Breast Cancer Relapse Predicts Higher Personalized Treatment Expectations
Nov 21, 2024
|
The HER2 low-expression group has a higher breast cancer recurrence prediction score (RS) than the HER2 negative group, according to the latest study. This study is meaningful in that it can be the basis for establishing a treatment strategy for the newly noted breast cancer treatment drug 'antibody-Drug Conjugates (ADC).
Professor Ahn Sung-gui and Professor Kook Yoon-won of breast surgery at Yonsei University's Gangnam Severance Hospital, and Professor Lee Sae-byeol of breast surgery at Asan Medical Center in Seoul began a study of 2,295 breast cancer patients who were positive for hormone receptors and HER2 negative from 2013 to 2020.
The research team classified the study group into HER2 low-expression group (1351, 58.9%) and HER2 negative group (944 and 41.1%), and then applied Oncotype Dx (Oncotype DX 21-gene multigene assay) tests to each group to examine the gene-based recurrence prediction score (RS).
As a result, the HER2-negative group average recurrence score was 17.802 and the HER2-low-expression group average recurrence score was 18.503, respectively, resulting in a significant result (p value < 0.05) that the HER2-low-expression group had a greater probability of breast cancer recurrence. Comparison of the high-risk RS ratio between the HER2-zero and HER2-low groups showed that the high-risk RS ratio was 12.4% (117 out of 944) in the HER2-zero group and the high-risk RS ratio was 17.0% (230 out of 1351) in the HER2-low group, showing statistically significant results (p value = 0.002).
In addition, the research team also reported a high-risk ratio with a predicted score of more than 26 for the HER2 low-expression group and HER2 negative group.Through multivariate analysis, the research team confirmed that the HER2 low-expression group had a higher risk ratio of 1.61 (95% CI 1.21-2.13) than the HER2 negative group to score more than 26 points for recurrence prediction.
Professor Ahn Sung-gui, who led the study, said "There have not been many studies analyzing molecular differences between the HER2 low-expression group and the existing HER2 negative group. This study is one of the largest studies to examine the correlation between recurrence prediction score and HER2 expression level, and we expect it to be a guide to subsequent studies for a customized treatment approach according to HER2 expression level."
This research paper was published in the latest issue of the international journal `Breast Cancer Research' under the title ' Analysis through Multiple Genetic Tests between HER2-low and HER2-zero Tumors in Hormone-positive HER2-negative breast cancer.
|
bellho@sportschosun.com
